Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3974200 | 0.91 | ACHE (0.40) | ACHEL3MBTL1LMNANR1I2MAOA | |
| SCHEMBL3974203 | 0.91 | ACHE (0.40) | ACHEL3MBTL1LMNANR1I2MAOA | |
| SCHEMBL3973868 | 0.80 | HTR2A (0.47) | ACHEL3MBTL1HTR2AALDH1A1MAPT | |
| SCHEMBL3980092 | 0.74 | ACHE (0.56) | ACHELMNANR1I2MAOAHTR2A | |
| SCHEMBL7281921 | 0.74 | L3MBTL1 (0.34) | L3MBTL1HTR2AALDH1A1TSHR | |
| SCHEMBL3977717 | 0.73 | ALDH1A1 (0.39) | ACHEL3MBTL1HTR2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3977324 | 0.73 | CRBN (0.42) | L3MBTL1LMNAMAOAOPRK1ALDH1A1 | |
| SCHEMBL1099201 | 0.72 | HTR2C (0.46) | ACHEL3MBTL1HTR2AALDH1A1PARP1 | |
| SCHEMBL3972863 | 0.71 | CYP11B2 (0.48) | ACHEHTR2AALDH1A1PARP1 | |
| SCHEMBL6406230 | 0.71 | DRD2 (0.51) | ACHEHTR2AALDH1A1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554240-B1 | SUBSTITUTED TETRALINS AND INDANES AND THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-06 | — | — | EP | disclosed |
| US-7351857-B2 | Methods of using substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-01 | — | — | US | disclosed |
| US-20060247314-A1 | Substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-02 | — | — | US | disclosed |
| US-20060094786-A1 | Treating syndrome X with substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-04 | — | — | US | disclosed |
| US-20060074130-A1 | Methods of using substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-06 | — | — | US | disclosed |
| EP-1569897-A1 | SUBSTITUTED TETRALINS AND INDANES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-09-07 | — | — | EP | disclosed |
| EP-1556344-A1 | TREATING SYNDROME X WITH SUBSTITUTED TETRALINS AND INDANES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-07-27 | — | — | EP | disclosed |
| EP-1554240-A1 | SUBSTITUTED TETRALINS AND INDANES AND THEIR USE | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-07-20 | — | — | EP | disclosed |
| US-20040171680-A1 | Treating Syndrome X with substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-02 | — | — | US | disclosed |
| US-20040167211-A1 | Methods of using substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-26 | — | — | US | disclosed |
| US-20040162352-A1 | Treating syndrome X with substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-19 | — | — | US | disclosed |
| WO-2004037779-A1 | SUBSTITUTED TETRALINS AND INDANES AND THEIR USE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037777-A1 | TREATING SYNDROME X WITH SUBSTITUTED TETRALINS AND INDANES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037778-A1 | SUBSTITUTED TETRALINS AND INDANES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094786-A1 | Treating syndrome X with substituted tetralins and indanes | PPARG, PPARA, PPARD | ACHE 4405/4885L3MBTL1 3840/4885LMNA 2061/4885 |
| US-20060074130-A1 | Methods of using substituted tetralins and indanes | PPARA, PPARG, PPARD | ACHE 4010/4885L3MBTL1 4440/4885LMNA 3361/4885 |
| US-20040171680-A1 | Treating Syndrome X with substituted tetralins and indanes | PPARG, PPARA, PPARD | ACHE 4405/4885L3MBTL1 3840/4885LMNA 2061/4885 |
| US-20040162352-A1 | Treating syndrome X with substituted tetralins and indanes | PPARG, PPARA, PPARD | ACHE 4405/4885L3MBTL1 3840/4885LMNA 2061/4885 |
| US-20040167211-A1 | Methods of using substituted tetralins and indanes | PPARA, PPARG, PPARD | ACHE 4010/4885L3MBTL1 4440/4885LMNA 3361/4885 |
| US-20060247314-A1 | Substituted tetralins and indanes | PPARA, PPARG, PPARD | ACHE 3487/4885L3MBTL1 3643/4885LMNA 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.